These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20591832)

  • 21. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab.
    Bacorro EA; Tehrani R
    J Clin Rheumatol; 2010 Aug; 16(5):237-9. PubMed ID: 20577094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
    Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.
    Vosslamber S; Raterman HG; van der Pouw Kraan TC; Schreurs MW; von Blomberg BM; Nurmohamed MT; Lems WF; Dijkmans BA; Voskuyl AE; Verweij CL
    Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 25. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
    Pusongchai T; Jungthirapanich J; Khositseth S
    J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.
    van Vollenhoven R; Gunnarsson I
    Arthritis Rheum; 2005 Dec; 52(12):4050-1; author reply 4051-2. PubMed ID: 16320358
    [No Abstract]   [Full Text] [Related]  

  • 27. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis.
    Iaccheri B; Androudi S; Bocci EB; Gerli R; Cagini C; Fiore T
    Ocul Immunol Inflamm; 2010 Jun; 18(3):223-5. PubMed ID: 20482403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lupus nephritis: a rituximab-based regimen might enable oral steroid avoidance in lupus nephritis.
    Killock D
    Nat Rev Rheumatol; 2013 Aug; 9(8):443. PubMed ID: 23797310
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting B-cells in lupus nephritis: should cautious optimism remain?
    Rovin BH
    Nephrol Dial Transplant; 2013 Jan; 28(1):7-9. PubMed ID: 22844105
    [No Abstract]   [Full Text] [Related]  

  • 30. Rituximab in refractory cutaneous polyarteritis.
    Krishnan S; Bhakuni DS; Kartik S
    Int J Rheum Dis; 2012 Oct; 15(5):e127. PubMed ID: 23083048
    [No Abstract]   [Full Text] [Related]  

  • 31. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).
    Pinto LF; Candia L; Garcia P; Marín JI; Pachón I; Espinoza LR; Marquez J
    Respiration; 2009; 78(1):106-9. PubMed ID: 18799870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Haug-Rost I; Braun J; Sieper J
    Ann Rheum Dis; 2013 Feb; 72(2):305-6. PubMed ID: 22887847
    [No Abstract]   [Full Text] [Related]  

  • 34. Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: a case report.
    Bienaimé F; Quartier P; Dragon-Durey MA; Frémeaux-Bacchi V; Bader-Meunier B; Patey N; Salomon R; Noël LH
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1346-50. PubMed ID: 20191570
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety of rituximab therapy during twins' pregnancy.
    Ton E; Tekstra J; Hellmann PM; Nuver-Zwart IH; Bijlsma JW
    Rheumatology (Oxford); 2011 Apr; 50(4):806-8. PubMed ID: 21177333
    [No Abstract]   [Full Text] [Related]  

  • 36. CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.
    Kamburova EG; Koenen HJ; Joosten I; Hilbrands LB
    Arthritis Rheum; 2013 Apr; 65(4):1130-1. PubMed ID: 23335076
    [No Abstract]   [Full Text] [Related]  

  • 37. Colitis associated with active systemic lupus erythematosus successfully treated with rituximab.
    Tayal V; Chiu YH; George E; Mane S
    J Clin Rheumatol; 2011 Mar; 17(2):79-82. PubMed ID: 21325960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Connective tissue diseases].
    Lorenz HM
    Dtsch Med Wochenschr; 2012 Mar; 137(13):661-3. PubMed ID: 22434176
    [No Abstract]   [Full Text] [Related]  

  • 40. The landscape after LUNAR: rituximab's crater-filled path.
    Lightstone L
    Arthritis Rheum; 2012 Apr; 64(4):962-5. PubMed ID: 22231618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.